Literature DB >> 31611957

Distinct expression pattern and prognostic values of pituitary tumor transforming gene family genes in non-small cell lung cancer.

Shaolong Yang1, Xiaodi Wang2, Jingxing Liu3, Bisha Ding4, Kairi Shi5, Jing Chen6, Weiyang Lou4.   

Abstract

Members of the pituitary tumor transforming gene (PTTG) family, including PTTG1, PTTG2 and PTTG3P, exhibit pivotal roles in the onset and progression of certain types of human cancer. However, to the best of our knowledge, a systematic study regarding the expression pattern and the prognostic values of PTTG family genes in non-small cell lung cancer (NSCLC) remains to be performed. The expression levels of PTTG family genes in NSCLC were successively determined using the Gene Expression Profiling Interactive Analysis, UALCAN and Oncomine databases. Subsequently, the Kaplan-Meier plotter database was used to assess the prognostic value of the PTTG family genes in patients with NSCLC, and to determine the associations between PTTG expression levels and the prognosis of patients based on different clinicopathological features, including cancer stage, grade, chemotherapy, radiotherapy, lymph node status, smoking history, and sex. PTTG1 was identified to be significantly upregulated in NSCLC in all three databases, whereas PTTG2 and PTTG3P were significantly upregulated in NSCLC in only the UALCAN database. Patients with NSCLC with higher expression levels of the three PTTG genes demonstrated shorter overall survival times. In summary, the results of the present study suggested that increased expression of PTTG family genes may serve as promising prognostic biomarkers for patients with NSCLC. Copyright: © Yang et al.

Entities:  

Keywords:  Kaplan-Meier plotter; Oncomine; UALCAN; gene expression profiling interactive analysis; in silico analysis; non-small cell lung cancer; pituitary tumor transforming gene; prognosis

Year:  2019        PMID: 31611957      PMCID: PMC6781778          DOI: 10.3892/ol.2019.10844

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

1.  Identification of the human pituitary tumor transforming gene (hPTTG) family: molecular structure, expression, and chromosomal localization.

Authors:  L Chen; R Puri; E J Lefkowitz; S S Kakar
Journal:  Gene       Date:  2000-05-02       Impact factor: 3.688

2.  Knockdown of PTTG1 inhibits the growth and invasion of lung adenocarcinoma cells through regulation of TGFB1/SMAD3 signaling.

Authors:  W-H Li; L Chang; Y-X Xia; L Wang; Y-Y Liu; Y-H Wang; Z Jiang; J Xiao; Z-R Wang
Journal:  Int J Immunopathol Pharmacol       Date:  2015-03       Impact factor: 3.219

3.  PTTG induces EMT through integrin αVβ3-focal adhesion kinase signaling in lung cancer cells.

Authors:  P P Shah; M Y Fong; S S Kakar
Journal:  Oncogene       Date:  2011-11-14       Impact factor: 9.867

4.  PTTG promotes invasion in human breast cancer cell line by upregulating EMMPRIN via FAK/Akt/mTOR signaling.

Authors:  Hui Gao; Feng Zhong; Jing Xie; Jianjun Peng; Zhiwu Han
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

5.  Human pituitary tumor transforming gene (hPTTG) inhibits human lung cancer A549 cell growth through activation of p21(WAF1/CIP1 ).

Authors:  Yi-Ming Mu; Koichi Oba; Toshihiko Yanase; Takeshi Ito; Kenji Ashida; Kiminobu Goto; Hidetaka Morinaga; Shoichiro Ikuyama; Ryoichi Takayanagi; Hajime Nawata
Journal:  Endocr J       Date:  2003-12       Impact factor: 2.349

6.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses.

Authors:  Zefang Tang; Chenwei Li; Boxi Kang; Ge Gao; Cheng Li; Zemin Zhang
Journal:  Nucleic Acids Res       Date:  2017-07-03       Impact factor: 16.971

7.  PTTG1 regulated by miR-146a-3p promotes bladder cancer migration, invasion, metastasis and growth.

Authors:  Wei Xiang; Xinchao Wu; Chao Huang; Miao Wang; Xian Zhao; Gang Luo; Yawei Li; Guosong Jiang; Xingyuan Xiao; Fuqing Zeng
Journal:  Oncotarget       Date:  2017-01-03

8.  Distinct prognostic values of mRNA expression of glutathione peroxidases in non-small cell lung cancer.

Authors:  Kui Liu; Meng Jin; Li Xiao; Huiguo Liu; Shuang Wei
Journal:  Cancer Manag Res       Date:  2018-08-28       Impact factor: 3.989

9.  Distinct prognostic values and potential drug targets of ALDH1 isoenzymes in non-small-cell lung cancer.

Authors:  Qinghua You; Huanchen Guo; Dongxiang Xu
Journal:  Drug Des Devel Ther       Date:  2015-09-03       Impact factor: 4.162

10.  Identification of potential miRNA-mRNA regulatory network contributing to pathogenesis of HBV-related HCC.

Authors:  Weiyang Lou; Jingxing Liu; Bisha Ding; Danni Chen; Liang Xu; Jun Ding; Donghai Jiang; Lin Zhou; Shusen Zheng; Weimin Fan
Journal:  J Transl Med       Date:  2019-01-03       Impact factor: 5.531

View more
  4 in total

1.  Simvastatin Suppresses Human Breast Cancer Cell Invasion by Decreasing the Expression of Pituitary Tumor-Transforming Gene 1.

Authors:  Litian Yin; Zhongmei He; Bing Yi; Linyuan Xue; Jianxin Sun
Journal:  Front Pharmacol       Date:  2020-11-04       Impact factor: 5.810

2.  MiR-625 Inhibits Tumor Cell Invasion, Migration and EMT by Negatively Regulating the Expression of Resistin in Non-Small Cell Lung.

Authors:  Yongsheng Zhao; Renyan Zheng; Dong Ning; Fei Xie
Journal:  Cancer Manag Res       Date:  2020-06-03       Impact factor: 3.989

3.  The Clinical Significance and Potential Molecular Mechanism of PTTG1 in Esophageal Squamous Cell Carcinoma.

Authors:  Shang-Wei Chen; Hua-Fu Zhou; Han-Jie Zhang; Rong-Quan He; Zhi-Guang Huang; Yi-Wu Dang; Xia Yang; Jun Liu; Zong-Wang Fu; Jun-Xian Mo; Zhong-Qing Tang; Chang-Bo Li; Rong Li; Li-Hua Yang; Jie Ma; Lin-Jie Yang; Gang Chen
Journal:  Front Genet       Date:  2021-01-22       Impact factor: 4.599

4.  Overexpressing PTTG family genes predict poor prognosis in kidney renal clear cell carcinoma.

Authors:  Yonghui Gui; Xueni Liu; Chao Wang; Peng Yang
Journal:  World J Surg Oncol       Date:  2021-04-12       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.